Osi Pharmaceuticals, Inc.

Andrew Kleinberg

Jing Wang

Mark Joseph Mulvihill

An-Hu Li

Arno G Steinig

Andrew Philip Crew

Meizhong Jin

Xin Chen

Hanqing Dong

Qinghua Weng

Bijoy Panicker

Dan Maarten Berger

Kam W Siu

James G Tarrant

Keith Hornberger

Ramesh C Gupta

Mridula Kadalbajoo

Lifu Ma

Melzhong Jin

Rajaram Sangem

Ti Wang

Compounds of Formula I, as shown below and defined herein: (I) pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by Ron and/or Met. 

Substituted pyrrolo[2,3-b]-pyridines and -pyrazines

Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention. 

Substituted imidazopyr- and imidazotri-azines

Compounds of Formula I, as shown below and defined herein:  pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.

Fused bicyclic kinase inhibitors

Compounds of Formula 1, as shown below and defined herein: 

7-aminofuropyridine derivatives

Furo[3,2-c]Pyridine and Thieno[3,2-c]pyridine compounds of Formula I, and pharmaceutically acceptable salts thereof, preparation, intermediates, pharmaceutical compositions, and use, such as in disease treatment, including cancers, including conditions in which EMT is involved, including conditions mediated by protein kinase activity such as RON and/or MET. 

Furo[3,2-C]pyridines

Growing community of inventors

East Meadow, NY, United States of America

Andrew Kleinberg